# A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets

> **NCT01322867** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** alprazolam tablet
- **DRUG:** alprazolam oral solution

## Key facts

- **NCT ID:** NCT01322867
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01322867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01322867, "A Bioequivalence Study Of A New Alprazolam Dropped Formulation Versus Alprazolam Tablets". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01322867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*